MedtronicMDT
MDT
About: One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Employees: 95,000
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
48% more first-time investments, than exits
New positions opened: 227 | Existing positions closed: 153
3.94% more ownership
Funds ownership: 78.97% [Q3] → 82.91% (+3.94%) [Q4]
2% more funds holding
Funds holding: 2,039 [Q3] → 2,077 (+38) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 31 [Q3] → 31 (+0) [Q4]
7% less call options, than puts
Call options by funds: $586M | Put options by funds: $632M
9% less capital invested
Capital invested by funds: $93.1B [Q3] → $85B (-$8.18B) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 775 | Existing positions reduced: 874
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$90
9%
upside
Avg. target
$98
18%
upside
High target
$107
30%
upside
5 analyst ratings
2 positive
40%
3 neutral
60%
0 negative
0%
Truist Securities Richard Newitter 54% 1-year accuracy 26 / 48 met price target | 9%upside $90 | Hold Maintained | 11 Apr 2025 |
Citigroup Joanne Wuensch 42% 1-year accuracy 18 / 43 met price target | 30%upside $107 | Buy Upgraded | 4 Mar 2025 |
RBC Capital Shagun Singh 36% 1-year accuracy 24 / 66 met price target | 27%upside $105 | Outperform Reiterated | 19 Feb 2025 |
UBS Danielle Antalffy 50% 1-year accuracy 6 / 12 met price target | 15%upside $95 | Neutral Maintained | 19 Feb 2025 |
Baird David Rescott 50% 1-year accuracy 8 / 16 met price target | 10%upside $91 | Neutral Maintained | 19 Feb 2025 |
Financial journalist opinion
Based on 16 articles about MDT published over the past 30 days
Neutral
PRNewsWire
1 day ago
New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved
Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland , April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync™ sensor for use with the MiniMed™ 780G system. With this approval, the MiniMed™ 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection™ technology with both the Guardian™ 4 sensor and Simplera Sync™ sensor.
Neutral
Zacks Investment Research
2 days ago
Medtronic (MDT) Stock Dips While Market Gains: Key Facts
Medtronic (MDT) concluded the recent trading session at $82.60, signifying a -0.12% move from its prior day's close.
Positive
The Motley Fool
1 week ago
3 Top Dividend Stocks to Buy and Hold for the Next 20 Years
Dividend stocks are great long-term investments. They've outperformed non-dividend-paying stocks by more than 2-to-1 over the long term.
Negative
Zacks Investment Research
2 weeks ago
Medtronic (MDT) Advances But Underperforms Market: Key Facts
In the latest trading session, Medtronic (MDT) closed at $88.86, marking a +0.42% move from the previous day.
Neutral
The Motley Fool
2 weeks ago
2 Value Stocks I'm Buying Right Now
Investing in this market isn't fun. Geopolitical tensions are escalating to levels not seen in decades, global trade relationships face unprecedented strain, and persistent inflation continues eroding purchasing power.
Positive
The Motley Fool
2 weeks ago
Why Medtronic Stock Marched Higher on Monday
Medtronic (MDT 2.62%) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by almost 3% in value. They liked the medical device specialist's latest piece of news about one of its products, and reacted accordingly.
Positive
Seeking Alpha
2 weeks ago
Best Dividend Aristocrats For April 2025
Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Brown (+20.65%), and AbbVie (+16.61%), showcasing strong double-digit gains. 29 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.15%.
Neutral
PRNewsWire
2 weeks ago
Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients
GALWAY, Ireland and CHICAGO , March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes.
Positive
The Motley Fool
3 weeks ago
Prediction: Buying Medtronic Today Will Set You Up for Life
Healthcare can be a complex sector, and it is one that I long ago decided to outsource to the industry professionals who run closed-end fund Blackrock Health Sciences Trust. But I couldn't resist dipping my toe into the sector when I saw the historically high yield on offer from Medtronic (MDT 0.88%), one of the largest and most diversified medical device makers.
Negative
Zacks Investment Research
3 weeks ago
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know
Medtronic (MDT) concluded the recent trading session at $88.98, signifying a +0.85% move from its prior day's close.
Charts implemented using Lightweight Charts™